Curis Q2 net loss $12.0M ($0.12/sh); FDA lifts partial clinical hold on TakeAim Leukemia study

CURIS INC

2023-Q2 EPS reported -$0.24 revenue$4,494,000

Net loss $12.0M ($0.12/sh) vs $15.9M ($0.17/sh) in Q2 2022; six-month net loss $23.5M ($0.24/sh).
Revenue $2.2M from Erivedge royalties; R&D expense $10.0M (down 19% YoY), G&A $4.2M (down 18% YoY).
FDA removed partial clinical hold on emavusertib TakeAim Leukemia study; confirmed RP2D at 300 mg BID.
Cash, equivalents and investments $77.4M after July registered direct offering ($13.8M net); runway into 2025.
Updated clinical data from monotherapy and combination studies expected in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

CURIS INC reported financial results for second quarter ended June 30, 2023.

Period: second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 3, 2023, Curis, Inc. announced its financial results for the three- and six-month periods ended June 30, 2023.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

CURIS INC reported financial results for six months ended June 30, 2023.

Period: six months ended June 30, 2023
Result: reported results

Exact text from the filing

On August 3, 2023, Curis, Inc. announced its financial results for the three- and six-month periods ended June 30, 2023.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

CURIS INC filing history →

Source: SEC EDGAR

accession 0001108205-23-000059

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.